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Objective—To describe vascular events during an 8 year follow-up in a multicentre SLE
inception cohort and their attribution to atherosclerosis.
Methods—Clinical data including co-morbidities are recorded yearly. Vascular events are
recorded and attributed to atherosclerosis or not. All events met standard clinical criteria. Factors
associated with atherosclerotic vascular events were analysed using descriptive statistics, t-tests
and χ2. Stepwise multivariate logistic regression was used to assess the association of factors with
vascular events attributed to atherosclerosis.
Results—Since 2000, 1249 patients have been entered into the cohort. There have been 97
vascular events in 72 patients. These include: myocardial infarction (13), angina (15), congestive
heart failure (24), peripheral vascular disease (8), transient ischemic attack (13), stroke (23),
pacemaker insertion (1). Fifty of the events were attributed to active lupus, 31events in 22 patients
were attributed to atherosclerosis, and 16 to other causes. Time from diagnosis to first
atherosclerotic event was 2.0 ± 1.5 years. Compared to patients followed for 2 years without
atherosclerosis events (615), at enrolment patients with AVE were more frequently Caucasian,
male, older at diagnosis of SLE, obese, smokers, hypertensive and had a family history of
coronary artery disease. On multivariate analysis only male gender and older age at diagnosis were
associated factors.
Conclusion—In an inception cohort with SLE followed for up to 8 years there were 97 vascular
events but only 31 were attributable to atherosclerosis. Patients with atherosclerotic events were
more likely to be male and to be older at diagnosis of SLE.
Background
Since the first description of the bimodal mortality pattern of systemic lupus erythematosus
(SLE) showing that coronary artery disease (CAD) is a significant cause of morbidity and
mortality in this condition, multiple studies have addressed the nature of these clinical
outcomes and the associated risk factors1. However, the exact incidence and prevalence of
atherosclerotic events is unknown. A few studies have attempted to identify risk factors for
CAD in lupus2,3,4,5. To date these studies have found elevated total cholesterol and older
age at diagnosis of SLE to be significantly associated with CAD. Other factors implicated in
one or two studies have been hypertension2,3, previous cardiac involvement with SLE,
obesity2, and longer duration of corticosteroid use3. However, lupus populations vary with
regard to organ involvement and it has not been possible to adequately address these
variables in the past, given the limited power of previous studies. Furthermore, incident SLE
subjects were rarely studied.
To address this complex clinical problem with appropriate epidemiologic tools in a
relatively uncommon disease such as SLE would be impossible without a concerted
international effort. The Systemic Lupus Erythematosus International Collaborating Clinics
(SLICC) is a group of rheumatologists and methodologists from 27 international centres
who have a particular interest and expertise in SLE. The co-operating centres all follow
large cohorts of SLE patients in standardized databases. The group has been working
together since 19876. SLICC has developed an international registry of newly diagnosed
SLE patients in order to provide a large diverse population to carry out a prospective
longitudinal study. One of the major objectives of the study is to determine the prevalence
and type of atherosclerotic vascular disease in SLE and to identify associated risk factors.
The SLICC group has shown that a significant number of coronary artery disease risk
factors are present within the first year of disease7.
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The aims of this SLICC investigation were to describe the vascular events occurring during
the first 8 years of follow-up and to attribute the vascular events to atherosclerosis.
Methods
The SLICC registry for atherosclerosis (SLICC-RAS)
Twenty-six SLICC centres from 11 countries, in North America, Europe and Asia
participated in this study. An inception cohort of 1249 SLE patients has been assembled
according to a standardized protocol between 2000 and 2008 to study risk factors for
atherosclerosis. Data collected includes clinical and laboratory features of lupus, CAD risk
factors and atherosclerotic outcomes based on a glossary of established definitions.
Patients
Patients are enrolled in the Registry within 15 months of their date of diagnosis, based on ≥4
American College of Rheumatology (ACR) classification criteria8. Demographic, clinical
and laboratory features of lupus, CAD risk factors and atherosclerotic outcome and
attribution data collected are submitted to the coordinating centre at the University of
Toronto at enrolment and once annually. Disease activity is measured by SLEDAI-2K9 and
adjusted mean SLEDAI-2K (AMS)10. Damage is measured by the SLICC/ACR damage
index11,12.
Definitions of atherosclerotic outcomes and attribution—Myocardial infarction
defined on the basis of definite electrocardiographic (ECG) abnormalities or symptoms of
chest pain with probable ECG abnormalities and abnormal cardiac enzymes, or typical
symptoms and abnormal cardiac enzymes, or fresh myocardial infarction or coronary
occlusion at post mortem13.
Attribution to atherosclerosis: SLE inactive at the time of the event (based on the treating
physician opinion and not associated with increase or new therapy); and any of typical
atherosclerotic changes on angiogram; evidence of atherosclerosis elsewhere
(cerebrovascular, peripheral vascular). Examinations to confirm these criteria were at the
discretion of the treating physician.
Angina: severe pain or discomfort over the upper or lower sternum or anterior left chest and
left arm on exertion, relieved at rest. Attribution to atherosclerosis: As above.
Congestive heart failure: Diagnosed clinically or on chest x-ray.
Attribution to atherosclerosis: As above
Insertion of pace maker attributed to atherosclerosis as above.
Intermittent claudication: classic symptoms including cramping pain and weakness in the
legs especially the calves on walking that disappears after rest.
Attribution to atherosclerosis: SLE inactive at the time of the event (based on the treating
physician opinion and not associated with increase or new therapy); typical atherosclerotic
changes on angiogram; evidence of atherosclerosis elsewhere (cardiac, cerebral vascular)
Transient ischemic attack (TIA): transient and completely reversible neurological deficit
with complete recovery within 24 hours.
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Attribution to atherosclerosis: SLE inactive at the time of the event (based on the treating
physician opinion and not associated with increase or new therapy); typical atherosclerotic
changes on angiogram; evidence of atherosclerosis elsewhere (cardiovascular, peripheral
vascular)
Stroke: irreversible or partially reversible motor and/or sensory deficits of sudden or recent
onset on the basis of vascular occlusion or insufficiency including complete or incomplete
stroke or stroke in evolution.
Attribution to atherosclerosis: as above.
Statistical analysis
Data presented for descriptive purposes are mean ± standard deviation (sd) for continuous
variables as well as percentages for categorical variables. Patients with atherosclerotic
vascular events were compared to patients with no atherosclerotic vascular events using t-
tests and chi-squared tests. Stepwise logistic regression analysis was used to determine the
contribution of multiple putative risk factors and their association to the presence of vascular
events attributed to atherosclerosis. Adequacy of model fit was established with Hosmer and
Lemeshow goodness-of-fit test. Factors included in the model were those which were
significantly different in the univariate analysis. Finally, comparisons between patients with
vascular events attributed to atherosclerosis to patients with events attributed to SLE were
made using non-parametric tests due to the small sample size, including Fisher’s exact test
and Wilcoxon rank sum test. A multivariate analysis was not conducted with the group of
patients because of sample size limitations.
Results
Characteristics of the SLICC-RAS cohort at enrolment
Of the 1249 patients enrolled, 1117 (89%) were female, 49% were Caucasian, 15% Black,
16% Hispanic, 16% Asian and 4% other. The mean age at presentation was 34 years, and
mean disease duration at entry to the cohort was 5.5 months. The average SLEDAI-2K was
5.5 and the majority were already on corticosteroid and antimalarial therapy (Table 1).
Vascular events
Ninety-seven vascular events occurred in 72 patients. The majority of the events (61) were
cardiovascular in nature including myocardial infarction −13; angina –15; congestive heart
failure –24; pacemaker insertion –1; peripheral vascular disease –8. Thirty six events were
cerebrovascular, including transient ischemic attacks –13 and stroke –23.
Attribution of vascular events
Of the 97 vascular events only 31 (in 22 patients) were attributed to atherosclerosis and
occurred at an average (± sd) of 2.0 (±1.5) years after entry into the cohort. Of the fourteen
events due to myocardial infarction, intermittent claudication or transient ischemic attack 10
were confirmed by imaging studies. Fifty of the 97 vascular events were attributed to active
lupus, and 16 to other causes (Table 2).
Baseline comparison of patients with and without atherosclerotic vascular events followed
for at least 2 years
Baseline variables for the 22 patients with atherosclerotic vascular events were compared to
615 SLE patients who did not have atherosclerotic vascular events and were followed for at
least 2 years. A two year follow up for the controls was chosen since the atherosclerotic
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vascular events occurred at an average of 2 years after entry into the cohort. Males make up
11% of the inception cohort but make up 41% of the patients with atherosclerotic events.
Other features of patients with atherosclerotic events are Caucasian ethnicity, older age at
diagnosis of SLE, hypertensive, obese, smokers, and with a positive family history for CAD
(Table 3). There was no difference at baseline in the frequency of hypercholesterolemia,
diabetes, use of corticosteroids, antimalarials or immunosuppressive drugs between patients
with and without atherosclerotic vascular events. SLEDAI-2K at presentation as well as
AMS at year 2 were similar in both groups. A stepwise multivariate analysis including the
items which were significant on the univariate analyses revealed only older age at diagnosis
(OR 1.08 95% CI (1.05, 1.11)) and male gender (OR 3.67, 95% CI (1.41, 9.52)) as
independently associated with atherosclerotic vascular events. Hosmer and Lemeshow
goodness-of-fit test p value = 0.59, indicating that the model fit is adequate.
Patients with vascular events due to lupus compared to those with atherosclerotic
vascular events
We then compared patients with atherosclerotic events to those with vascular events due to
lupus (Table 4). Male gender, older age at diagnosis, Caucasian race and use of antimalarials
at baseline were associated with atherosclerotic vascular events.
Discussion
This study reports on atherosclerotic events in an international inception cohort of patients
with SLE. Of the 97 vascular events documented among the 1249 patients, only 31 events
were attributable to atherosclerosis. These events occurred within 2 years of entry into the
cohort, or approximately 2.5 years from diagnosis. In long-term follow up studies the
prevalence of atherosclerotic vascular events varies from 8–13%14,15 and usually occurs at a
mean of 8–9 years from diagnosis1,15.
This study describes atherosclerotic vascular events in 22 of 1249 (1.8%) patients. As
previously noted, SLE patients with atherosclerotic vascular events tend to be older at SLE
diagnosis than those without these events3,2. In this study patients with atherosclerotic
vascular events were twenty years older than those without events, accounting in part for the
earlier onset of atherosclerotic vascular events (within 2.5 years of SLE diagnosis) in this
inception cohort. In univariate analyses patients with vascular events due to atherosclerosis
were more likely to have the classic risk factors for atherosclerotic disease than patients
without atherosclerotic vascular events who had been followed for at least 2 years. They
were more likely to be male, older, hypertensive, obese, smoker and have a family history of
CAD. Disease activity at presentation and over the first two years was similar in patients
who had atherosclerotic vascular events and patients who did not. There was also no
difference in the baseline use of medications between the two groups. However, in
multivariate analysis only male gender and older age remained independently associated
with atherosclerotic vascular events.
In the Baltimore study of 229 patients, 29 events were reported. In a multivariate analysis,
patients with events had higher cholesterol, history of hypertension, a longer mean SLE
duration and greater duration and use of corticosteroids (Table 5). However, although the
cohort was followed for 4 years, it was a prevalent cohort with mean SLE disease duration
in those with atherosclerotic vascular events of 12 years compared to 8 years in those
without2. In the Pittsburgh cohort, also a prevalent cohort of 498 women, there were 33
events. The risk factors identified in a multivariate analysis included older age at diagnosis,
longer SLE duration , longer duration of corticosteroid use, hypercholesterolemia and
postmenopausal status. In this cohort, the SLE disease duration in those with atherosclerotic
vascular events was 13.0 years compared to 10.0 in those without3. In the LUMINA cohort,
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which includes patients within 5 years of diagnosis, of 546 patients there were 34 vascular
events including angina, myocardial infarction, vascular interventions, strokes and
peripheral vascular events. Risk factors identified in multivariate analysis included older
age, current smoking status, longer follow-up time, elevated C-reactive protein and the
presence of antiphospholipid antibody16. In the Toronto cohort, of 1087 patients who did not
have atherosclerotic vascular events prior to entry to the cohort, 144 atherosclerotic vascular
events were documented. In a multivariate analysis of risk factors for atherosclerotic
vascular events, neuropsychiatric disease, vasculitis and number of Framingham CAD risk
factors were associated with coronary artery events15. In the inception patients in the
Toronto Cohort which included 561 patients seen within 1 year of diagnosis and followed
through 9 years of follow-up 9.6% had atherosclerotic vascular events. A multivariate
analysis of risk factors for atherosclerotic vascular events revealed neuropsychiatric disease
and smoking to be associated with atherosclerotic vascular events15.
In the two inception cohorts with disease duration at entry of less than 1 year (the Toronto
inception cohort and the current SLICC/RAS cohort study), the classic Framingham risk
factors were not clearly independently associated with atherosclerotic vascular events, as
there has been a shorter exposure to these risk factors perhaps mitigating their impact. It is
possible that over time these risk factors will exert their influence. Furthermore, the
LUMINA, the Toronto and the SLICC studies included cerebrovascular and peripheral
vascular atherosclerotic vascular events while the Baltimore and Pittsburgh studies included
only coronary artery disease events. While there were no cerebrovascular accidents reported
in the current study there were two instances of transient ischemic attack and four with
peripheral vascular disease. This difference in outcomes might have an effect on the nature
of the associated factors.
We have previously demonstrated in this cohort that risk factors for atherosclerotic disease
accumulate early in the course of the disease17. However as suggested earlier, these risk
factors have not yet exerted their full impact. In early disease it is likely that male gender
and older age states associated with increased risk factors for atherosclerotic vascular events
are dominant. This should not deter from the necessity for aggressive intervention in the
treatment of classic CAD risk factors.
Atherosclerotic vascular events documented in this cohort included cardiac, cerebrovasular
and peripheral vascular events. Cardiac and cerebral events are common disease features of
SLE. These clinical presentations often pose a diagnostic challenge as they are often
confounded by co-morbid conditions. As well atherosclerotic events may mimic SLE
presentations for example chest pain and stroke syndromes can be on the basis of active SLE
or atherosclerosis. Furthermore, this is made more difficult by the fact that the patients who
presented with atherosclerotic vascular events early in the course of their SLE disease had
similar risk factors to patients who presented with a lupus vascular event except with regards
to older age at diagnosis, Caucasian race and use of antimalarials. Unlike other studies
where antimalarials have been suggested to be protective for atherosclerotic or thrombotic
disease, in the current study patients with atherosclerotic events more often took
antimalarials than those who did not have atherosclerotic events18,19,20. The reason for this
is unclear. While it is possible that patients with atherosclerotic events had had more severe
disease prior to enrolling in the SLICC-RAS, at two years, patients without atherosclerotic
events actually had higher disease activity measured by the AMS. Thus the reason for the
lower use of antimalarials in these patients is unknown. Clinicians must adopt attribution
rules, as used in this study, to differentiate those events due to the disease itself from those
due to atherosclerosis. In addition to the clinical attribution rules, most patients in this study
had confirmatory laboratory and imaging studies.
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A limitation of this study is the relatively short duration of follow-up of an inception cohort
and therefore the number of events is small. Nevertheless, 31 events in 22 patients were
detected within 2.5 years of diagnosis, highlighting the fact that in some individuals (older
males) these events may occur very early in the disease. Another possible limitation is the
interval between assessments being one year, which may not reveal the full impact of
disease activity on the development of atherosclerotic events. The strengths of this study are
the size of the inception cohort, its multiethnic composition, the uniform collection of data
on a common data retrieval protocol, and the use of standardized clinical attribution rules for
atherosclerotic vascular events. Nevertheless in patients with known atherosclerotic disease
active lupus may make the attribution of an event more difficult, and in cases of active lupus
subclinical atherosclerosis may be missed. However, in the majority of cases the attribution
rules helped clarify the situation. Patients in this cohort will continue to be followed for 5
years.
Acknowledgments
We are grateful for the generous donation of our patients’ time and the dedication of all the fellows, research
coordinators and research assistants in the SLICC network to the completion of this work.
Support: Dr. Urowitz’s work was supported by the Canadian Institutes of Health Research (grant MOP-49529), the
Lupus Foundation of Ontario, the Ontario Lupus Association, Lupus UK, the Lupus Foundation of America, the
Lupus Alliance of Western New York, the Conn Smythe Foundation, The Lupus Flare Foundation, and the Tolfo
family of Toronto, Ontario, Canada. Dr. Bae’s work was supported by the Brain Korea 21 Program. Dr. Gordon’s
work was supported by Lupus UK, the Arthritis Research Campaign, and the Wellcome Trust Clinical Research
Facility, Birmingham, UK. Dr Alarcón’s work was supported by the University of Alabama at Birmingham (NIH/
NIAMS grant P60-AR-48095). Dr. Clarke’s work was supported by the Singer Family Fund for Lupus Research;
she is also a Fonds de la Recherche en Sante du Quebec National Scholar. Dr. Bernatsky’s work was supported by
the Fonds de la Recherche en Sante du Quebec Jeune Chercheure and the McGill University Health Centre
Research Institute; she is also a recipient of a Canadian Institutes of Health Research Junior Investigator Award and
a Canadian Arthritis Network Scholar Award. Dr. Fortin is a Distinguished Senior Investigator of The Arthritis
Society with additional support from the Arthritis Centre of Excellence, University of Toronto. Dr. Hanly’s work
was supported by a grant from the Canadian Institutes of Health Research. Dr. Gladman’s work was supported by
the Canadian Institutes of Health Research. Dr. Petri’s work was supported by the Hopkins Lupus Cohort (grant
AR-43727) and the Johns Hopkins University General Clinical Research Center (grant M01-RR-00052). Drs.
Nived and Sturfelt’s work was supported by the Swedish Medical Research Council (grant 13489). Dr. Ramsey-
Goldman’s work was supported by the NIH (grants UL 1RR 025741, K24-AR-02318, and P60-AR-48098).
References
1. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The Bimodal
Mortality in Systemic Lupus Erythematosus. Am J Med. 1976; 60:221–225. [PubMed: 1251849]
2. Petri M, Perez-Gutthan S, Spence D, Hochberg MC. Risk factors for coronary artery disease in
patients with systemic lupus erythematosus. Amer J Med. 1992; 93:513–519. [PubMed: 1442853]
3. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and
angina in women with Systemic Lupus Erythematosus: comparison with the Framingham study.
Amer J Epidemiol. 1997; 145:408–15. [PubMed: 9048514]
4. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol. 1987;
14(Suppl 13):223–6.
5. Manzi S, Selzer F, Sutton-Tyrrel K, Fitzgerald S, Rairie JE, Tracy RP, Kuller LH. Prevalence and
risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999;
42:51–60. [PubMed: 9920014]
6. Isenberg DA, Gladman DD. The Systemic Lupus International Collaborating Clinics Group –
Origins and outcomes. Lupus. 2001; 10:375–77. [PubMed: 11403271]
7. Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al. Clinical
manifestations and coronary artery disease risk factors at diagnosis of Systemic Lupus
Erythematosus: Data from an international inception cohort. Lupus. 2007; 16:731–735. [PubMed:
17728367]
UROWITZ et al. Page 7













8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the
classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40:1725. [PubMed:
9324032]
9. Gladman DD, Ibañez D, Urowitz MB. SLE Disease Activity Index 2000. J Rheumatol. 2002;
29:288–291. [PubMed: 11838846]
10. Ibañez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean
SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol. 2003;
30:1977–1982. [PubMed: 12966601]
11. Gladman DD, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, et al.
Development and Initial Validation of the SLICC/ACR Damage Index for SLE. Arthritis Rheum.
1996; 39:363–9. [PubMed: 8607884]
12. Gladman DD, Urowitz MB, Goldsmith C, Fortin P, Ginzler E, Gordon C, et al. The Reliability of
the SLICC/ACR Damage Index in Patients with SLE. Arthritis Rheum. 1997; 40:809–13.
[PubMed: 9153540]
13. Tustall-Pedoe H, Kuulasmaa K, Abouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial
infarction and coronary deaths in the World Health Organization MONICA project. Registration
procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four
continents. Circulation. 1994; 90:583–612. [PubMed: 8026046]
14. Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus
erythematosus. Rheum Dis Clin North Am. 2005; 31:329–354. [PubMed: 15922149]
15. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events (AVE) in a single large
lupus cohort: prevalence and risk factors. J Rheumatol. 2007; 34:70–75. [PubMed: 17117488]
16. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, et al. Systemic lupus
erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular
events. Arthritis Rheum. 2004; 50:3947–3957. [PubMed: 15593203]
17. Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, et al. Accumulation of
coronary artery disease risk factors over three years: data from an international inception cohort.
Arthritis Rheum. 2008; 59:176–180. [PubMed: 18240193]
18. Urowitz MB, Gladman DD, Tom BDM, Ibañez D, Farewell VT. Changing Patterns in Mortality
and Disease Outcome for Patients with Systemic Lupus Erythematosus. J Rheumatol. 2008;
35:2152–2158. [PubMed: 18793004]
19. Alarcon GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of
patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort. Ann
Rheum Dis. 2007; 66:1168–72. [PubMed: 17389655]
20. Ruiz-Irastorza G, Egurginde MB, Pijoan JI, et al. Effect of antimalarials on thrombosis and
survival in patients with systemic lupus erythematosus. Lupus. 2006; 15:577–83. [PubMed:
17080912]
UROWITZ et al. Page 8

























UROWITZ et al. Page 9
Table 1
Characteristics of the SLICC-RAS cohort at enrolment (n=1249)
Gender – Female – n (%) 1117 (89.4%)
Race/Ethnicity - (%) Caucasian / Black / Hispanic / Asian/Other 49/ 15 / 16 / 16 / 4
Age at diagnosis – years 34.3 ± 13.3
Disease duration – months 5.5 ± 4.1
SLEDAI-2K – mean ± sd 5.49 ± 5.59
Corticosteroids – n (%) 849 (69.7%)
Immunosuppressives – n (%) 485 (39.8%)
Antimalarials – n (%) 771 (63.3%)













UROWITZ et al. Page 10
Table 2
Attribution of vascular events
Attributed to Atherosclerosis Attributed to Active SLE Attributed to Other Causes*
Number of events 31 50 16
Stroke 20 3
Congestive Heart Failure 5 12 7
Transient Ischemic Attack 2 10 1
Peripheral Vascular Disease 4 3 1
Angina 12 2 1








Vertebral artery dissection 1
Pulmonary disease 1
Gastrointestinal bleed 1
Renal failure on dialysis 1
Coronary artery spasm 1
Hypertension 1
Unknown 2
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Table 3
A comparison between patients with atherosclerotic vascular events due to atherosclerosis with all other
patients
At Enrolment Patients with AVE All other Patients* P value
No. of patients 22 615
Caucasian 17 (77.3%) 328 (53.3%) 0.03
Male 9 (40.9%) 72 (11.7%) <0.0001
Age at Diagnosis 54.6 ± 13.1 34.6 ± 13.7 < 0.0001
Hypertension 14 (73.6%) 197 (32.3%) 0.002
Obese (BMI >27 F >25 M) 12 (57.1%) 163 (28.1%) 0.004
Smoker (Current or Ex) 14 (63.6%) 225 (36.6%) 0.01
Family History CAD (adjusted for age) ** 9 (42.9%) 117 (20.0%) 0.02
Hypercholesterolemia 12 (54.6%) 228 (37.4%) 0.10
Diabetes mellitus 2 (10.5%) 14 (2.4%) 0.08
Corticosteroids 17 (77.3%) 417 (68.5%) 0.38
Antimalarials 16 (72.7%) 386 (63.5%) 0.38
Immunosuppressive drug use 6 (27.3%) 227 (37.3%) 0.34
SLEDAI-2K at presentation 3.32 ± 3.09 5.53 ± 5.63 0.11
AMS at Year 2 3.02 ± 3.11 4.15 ± 3.78 0.12
*
Followed for at least 2 years, AMS=adjusted mean SLEDAI-2K
**
first degree relative Female < 65 years old or Male < 55 years old
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Table 4
A comparison between patients with vascular events due to atherosclerosis to patients with vascular events
due to SLE.
Patients with vascular events due to AS Patients with vascular events due to SLE P value
No. of patients* 22 42
Caucasian 17 (77.3%) 21 (50.0%) 0.03
Male 9 (40.9%) 8 (19.1%) 0.06
Age at Diagnosis 54.6 ± 13.1 41.2 ± 13.8 0.0004
Hypertension 14 (63.6%) 28 (66.7%) 0.81
Obese (BMI >27 F >25 M) 12 (57.1%) 15 (36.6%) 0.12
Diabetes mellitus 2 (10.5%) 1 (2.4%) 0.23
Smoker (Current or Ex) 14 (63.6%) 16 (38.1%) 0.052
Family Hx CAD (adjusted for age) ** 9 (42.9%) 13 (31.7%) 0.39
Hypercholesterolemia 12 (54.6%) 19 (45.2%) 0.48












Corticosteroids 17 (77.3%) 30 (71.4%) 0.62
Antimalarials 16 (72.7%) 15 (36.6%) 0.006
Immunosuppressive drug use 6 (27.3%) 21 (50.0%) 0.08
SLEDAI-2K 3.32 ± 3.09 5.93 ± 7.47 0.43
AMS at Year 2 3.02 ± 3.11 4.91 ± 4.82 0.15
*
There were 31 atherosclerotic vascular events in 22 patients, and 50 vascular events due to SLE in 42 patients.
**
first degree relative Female < 65 years old or Male < 55 years old.
***
anticardiolipin antibody or lupus anticoagulant AMS=adjusted mean SLEDAI-2K
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